Development of an In Situ Anhydrobiotic Tissue Culture Process

原位脱水组织培养工艺的开发

• 批准号: 7481983
• 负责人: John M BAUST
• 金额: $ 25.15万
• 依托单位: CELL PRESERVATION SERVICES, INC.
• 依托单位国家: 美国
• 财政年份: 2008
• 资助国家: 美国
• 起止时间: 2008-05-15 至 2009-11-14
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7481983
• 关键词: Address; Apoptosis; Biochemical; Biological; Biological Preservation; Biological Process; Biotechnology; Cell Cycle; Cell Cycle Progression; Cell Cycle Stage; Cell Death; Cell Line; Cell Survival; Cell physiology; Cells; Cellular Stress Response; Class; Complement 3a; Cryopreservation; Cultured Cells; Cytochromes; Depth; Desiccation; Development; Disruption; Drug Formulations; Engineering; Event; Failure; Fas Signaling Pathway; Freezing; Hepatocyte; Hour; Human; In Situ; Industry; Investigation; Knowledge; Life; Maintenance; Mammalian Cell; Mediating; Membrane; Metabolic; Methods; Mitochondria; Modification; Molecular; Necrosis; Organ; Organism; Oxidative Stress; Pathway interactions; Pharmacologic Substance; Phase; Physiological; Process; Production; Public Health; Recovery; Regenerative Medicine; Rehydrations; Research; Research Proposals; Role; Services; Signal Transduction; Signaling Molecule; Small Business Funding Mechanisms; Small Business Innovation Research Grant; Staging; Standards of Weights and Measures; Stem Cell Research; Stem cells; Surface; System; Techniques; Technology; Testing; Therapeutic; Thinking; Time; Time Management; Tissue Engineering; Tissues; Today; base; biodefense; biological adaptation to stress; caspase-9; cell type; cold temperature; concept; day; design; drug discovery; human AMID protein; improved; information gathering; innovative technologies; keratinocyte; natural hypothermia; novel; receptor; research and development; response; restoration; stem cell therapy; tissue culture

DESCRIPTION (provided by applicant): Cell Preservation Services, Inc. (CPSI) is an early stage biotechnology company that intends to develop a unique technology that will facilitate both the time- management and worldwide distribution of human cell cultures in a manner that currently does not exist. Under this SBIR, CPSI intends to develop a ready-to- use pre-seeded cell culture product, DryPlates", for several cell types, including standard cell lines, primary cells, such as keratinocytes or hepatocytes, and progenitor cells. This technology will allow users on-demand access to cells for high-throughput usage while eliminating the need for extensive handling and culturing of cells prior to utilization. The design of DryPlates" products provides for the long-term stable non-frozen storage of biologicals in a convenient format, easily integratable with current methods. CPSI intends to investigate the cellular and molecular components of the anhydrobiotic process to develop a technology and method of production of DryPlates" to meet the needs of industry, including pharmaceutical drug discovery, biodefense and stem cell research. PUBLIC HEALTH RELEVANCE: This proposal is designed to develop a unique and innovative technology for the worldwide distribution of human cell cultures to be used in the pharmaceutical and biomedical industries.

描述（由申请人提供）：Cell Preservation Services，Inc.（CPSI）是一家处于早期阶段的生物技术公司，打算开发一种独特的技术，以目前尚不存在的方式促进人类细胞培养物的时间管理和全球分销。根据该SBIR，CPSI打算开发一种即用型预接种细胞培养产品“DryPlates”，用于多种细胞类型，包括标准细胞系、原代细胞（例如角质形成细胞或肝细胞）和祖细胞。该技术将允许用户按需访问细胞以进行高通量使用，同时消除了在使用前对细胞进行大量处理和培养的需要。DryPlates”产品的设计以方便的形式提供了生物制品的长期稳定的非冷冻储存，易于与当前方法集成。CPSI打算研究脱水生物过程的细胞和分子组成部分，以开发一种生产DryPlates的技术和方法，以满足工业的需求，包括药物发现，生物防御和干细胞研究。公共卫生相关性：该提案旨在开发一种独特的创新技术，用于制药和生物医学行业的人类细胞培养物的全球分销。